Nyxoah’s Involvement in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Nyxoah, a medical technology company based in Mont-Saint-Guibert, Belgium, is set to participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 12 – 13, 2024. The company, known for its focus on developing innovative solutions to treat Obstructive Sleep Apnea (OSA), will have its Chief Executive Officer, Olivier Taelman, deliver a corporate presentation during the event at 10:40am ET on March 12.

Nyxoah’s lead solution, the Genio® system, is a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, a common sleep-disordered breathing condition associated with various health risks. With a vision to help OSA patients enjoy restful nights and live life to the fullest, Nyxoah has achieved significant milestones, including receiving European CE Mark in 2019 and conducting successful IPOs on Euronext Brussels and NASDAQ.

Currently, Nyxoah is focused on obtaining FDA approval and U.S. commercialization for its Genio® system through the ongoing DREAM IDE pivotal study. For more information about Nyxoah and its revolutionary treatment for OSA, visit their website at http://www.nyxoah.com/.

As a cautionary note, Nyxoah’s Genio® system has been CE marked since 2019 and is considered an investigational device in the United States, limited to investigational use under U.S. federal law.

For further inquiries, please contact Nyxoah’s Chief Strategy Officer, David DeMartino, at david.demartino@nyxoah.com or by phone at +1 310 310 1313.